281 related articles for article (PubMed ID: 21831227)
21. Post-transplant therapy with high-dose intravenous gammaglobulin: Applications to treatment of antibody-mediated rejection.
Jordan SC; Vo AA; Toyoda M; Tyan D; Nast CC
Pediatr Transplant; 2005 Apr; 9(2):155-61. PubMed ID: 15787786
[TBL] [Abstract][Full Text] [Related]
22. Alloantibodies and the outcome of cadaver kidney allografts.
Vasilescu ER; Ho EK; Colovai AI; Vlad G; Foca-Rodi A; Markowitz GS; D'Agati V; Hardy MA; Ratner LE; Suciu-Foca N
Hum Immunol; 2006 Aug; 67(8):597-604. PubMed ID: 16916655
[TBL] [Abstract][Full Text] [Related]
23. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation.
Patel J; Everly M; Chang D; Kittleson M; Reed E; Kobashigawa J
J Heart Lung Transplant; 2011 Dec; 30(12):1320-6. PubMed ID: 21968130
[TBL] [Abstract][Full Text] [Related]
24. Factors associated with and predictive of persistence of donor-specific antibody after treatment with plasmapheresis and intravenous immunoglobulin.
Zachary AA; Montgomery RA; Leffell MS
Hum Immunol; 2005 Apr; 66(4):364-70. PubMed ID: 15866699
[TBL] [Abstract][Full Text] [Related]
25. Desensitization protocols and their outcome.
Marfo K; Lu A; Ling M; Akalin E
Clin J Am Soc Nephrol; 2011 Apr; 6(4):922-36. PubMed ID: 21441131
[TBL] [Abstract][Full Text] [Related]
26. Proteasome inhibitor treatment of antibody-mediated allograft rejection.
Woodle ES; Alloway RR; Girnita A
Curr Opin Organ Transplant; 2011 Aug; 16(4):434-8. PubMed ID: 21753709
[TBL] [Abstract][Full Text] [Related]
27. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy.
Reinsmoen NL; Lai CH; Vo A; Cao K; Ong G; Naim M; Wang Q; Jordan SC
Transplantation; 2008 Sep; 86(6):820-5. PubMed ID: 18813107
[TBL] [Abstract][Full Text] [Related]
28. Hidden perils in a highly sensitized kidney transplant recipient.
Ford S; Summers S; Cantwell L; Mulley W
Nephrology (Carlton); 2012 Apr; 17 Suppl 1():9-11. PubMed ID: 22497647
[TBL] [Abstract][Full Text] [Related]
29. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
[TBL] [Abstract][Full Text] [Related]
30. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
Lee PC; Ozawa M
Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
[TBL] [Abstract][Full Text] [Related]
31. [The highly sensitized patient. Therapeutic alternatives for kidney transplantation].
Mancilla-Urrea E
Rev Invest Clin; 2005; 57(2):206-12. PubMed ID: 16524060
[TBL] [Abstract][Full Text] [Related]
32. Desensitizing the broadly human leukocyte antigen-sensitized patient awaiting deceased donor kidney transplantation.
Jordan SC; Reinsmoen N; Lai CH; Cao K; Kahwaji J; Peng A; Villicana R; Vo A
Transplant Proc; 2012 Jan; 44(1):60-1. PubMed ID: 22310579
[TBL] [Abstract][Full Text] [Related]
33. Long-term experience of plasmapheresis in antibody-mediated rejection in renal transplantation.
Brown CM; Abraham KA; O'Kelly P; Conlon PJ; Walshe JJ
Transplant Proc; 2009 Nov; 41(9):3690-2. PubMed ID: 19917368
[TBL] [Abstract][Full Text] [Related]
34. Utility of peritransplant and rescue intravenous immunoglobulin and extracorporeal immunoadsorption in lung transplant recipients sensitized to HLA antigens.
Appel JZ; Hartwig MG; Davis RD; Reinsmoen NL
Hum Immunol; 2005 Apr; 66(4):378-86. PubMed ID: 15866701
[TBL] [Abstract][Full Text] [Related]
35. Desensitization in kidney transplantation: review and future perspectives.
Abu Jawdeh BG; Cuffy MC; Alloway RR; Shields AR; Woodle ES
Clin Transplant; 2014 Apr; 28(4):494-507. PubMed ID: 24621089
[TBL] [Abstract][Full Text] [Related]
36. Prevention of antibody-mediated kidney transplant rejection.
Morath C; Opelz G; Zeier M; Süsal C
Transpl Int; 2012 Jun; 25(6):633-45. PubMed ID: 22587522
[TBL] [Abstract][Full Text] [Related]
37. Immunoadsorption in acute vascular rejection after renal transplantation.
Persson NH; Bucin D; Ekberg H; Källén R; Omnell Persson M; Simanaitis M; Sterner G; Swedenborg P
Transplant Proc; 1995 Dec; 27(6):3466. PubMed ID: 8540054
[No Abstract] [Full Text] [Related]
38. Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch utilizing peri-operative plasmapheresis and cytolytic therapy.
Holt DB; Lublin DM; Phelan DL; Boslaugh SE; Gandhi SK; Huddleston CB; Saffitz JE; Canter CE
J Heart Lung Transplant; 2007 Sep; 26(9):876-82. PubMed ID: 17845925
[TBL] [Abstract][Full Text] [Related]
39. Desensitization for prevention of chronic antibody-mediated rejection after kidney transplantation.
Tanabe K; Inui M
Clin Transplant; 2013; 27 Suppl 26():2-8. PubMed ID: 24299229
[TBL] [Abstract][Full Text] [Related]
40. Desensitization in the Setting of HLA-Incompatible Kidney Transplant.
Malvezzi P; Jouve T; Noble J; Rostaing L
Exp Clin Transplant; 2018 Aug; 16(4):367-375. PubMed ID: 29863455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
